Sernova (TSE:SVA) has released an update.
Sernova Corp., a biotech firm advancing regenerative medicine for chronic diseases, announced a presentation at the EASD Annual Meeting to discuss new data from its Cell Pouch System™ trial for Type 1 Diabetes. The innovative Cell Pouch System™, aiming to be a ‘functional cure’ for insulin-dependent diabetes, has shown promising interim results in a Phase I/II clinical trial conducted by the University of Chicago’s islet transplant team.
For further insights into TSE:SVA stock, check out TipRanks’ Stock Analysis page.
